Journal
ENDOCRINOLOGIA Y NUTRICION
Volume 63, Issue 5, Pages 239-249Publisher
ELSEVIER ESPANA SLU
DOI: 10.1016/j.endonu.2016.01.001
Keywords
Statins; HMG-CoA reductase inhibitors; Ditag-related side effect; Statin intolerance; Myotoxicity; Myopathy
Categories
Ask authors/readers for more resources
Statin therapy has a very important role in decreasing cardiovascular risk, and treatment non-compliance may therefore be a concern in high cardiovascular risk patients. Myotoxicity is a frequent side effect of statin therapy and one of the main causes of statin discontinuation, which limits effective treatment of patients at risk of or with cardiovascular disease. Because of the high proportion of patients on statin treatment and the frequency of statinrelated myotoxicity, this is a subject of concern in clinical practice. However, statin-related myotoxicity is probably underestimated because there is not a gold standard definition, and its diagnosis is challenging. Moreover, information about pathophysiology and optimal therapeutic options is scarce. Therefore, this paper reviews the knowledge about the definition, pathophysiology and predisposing conditions, diagnosis and management of statin-related myotoxicity, and provides a practical scheme for its management in clinical practice. (C) 2016 SEEN. Published by Elsevier Espana, S.L.U. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available